RSRenu Singh

Renu Singh

*This is an algorithmically generated author record based on publicly available information.

Renu Singh has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Ann E. Eakin

    AstraZeneca Infection Innovative Medicines , 35 Gatehouse Drive, Waltham, MA 02451 , USA

    1 shared publication
  • April Chen

    Infection Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, MA 02451, USA

    1 shared publication
  • Aryun Kim

    AstraZeneca Infection Innovative Medicines , 35 Gatehouse Drive, Waltham, MA 02451 , USA

    1 shared publication
  • Jane E Ambler

    Infection Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, MA 02451, USA

    1 shared publication
  • Jennifer J. Harris

    AstraZeneca Infection Innovative Medicines , 35 Gatehouse Drive, Waltham, MA 02451 , USA

    1 shared publication
  • John P. O'DOnnell

    AstraZeneca Infection Innovative Medicines , 35 Gatehouse Drive, Waltham, MA 02451 , USA

    1 shared publication

Latest Publications

  • Open Access

    Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model

    by Renu Singh, Mashal Almutairi, Richard A Alm, Sushmita D Lahiri, Maryann San Martin, April Chen, Jane E Ambler

    The current CLSI and EUCAST clinical susceptible breakpoint for 600 mg q12h dosing of ceftaroline (active metabolite of ceftaroline fosamil) for Staphylococcus aureus is ≤1 mg/L. Efficacy data for S. aureus infections with ceftaroline MIC ≥2 mg/L are limited. This study was designed to generate in-depth pharmacokinetic/pharmacodynamics (PK/PD) understanding of S. aureus isolates inhibited by ≥ 2 mg/L ceftaroline using an in vitro hollow-fibre infection model (HFIM). The PK/PD target of ceftaroline was investigated against 12 diverse characterized clinical MRSA isolates with ceftaroline MICs of 2 or 4 mg/L using q8h dosing for 24 h. These isolates carried substitutions in the penicillin-binding domain (PBD) and/or the non-PBD. Additionally, PD responses of mutants with ceftaroline MICs ranging from 2 to 32 mg/L were evaluated against the mean 600 mg q8h human-simulated dose over 72 h. The mean stasis, 1 log10-kill and 2 log10-kill PK/PD targets were 29%, 32% and 35% f T>MIC, respectively. In addition, these data suggest that the PK/PD target for MRSA is not impacted by the presence of substitutions in the non-PBD commonly found in isolates with ceftaroline MIC values of ≤ 2 mg/L. HFIM studies with 600 mg q8h dosing demonstrated a sustained long-term bacterial suppression for isolates with ceftaroline MICs of 2 and 4 mg/L. Overall, efficacy was demonstrated against a diverse collection of clinical isolates using HFIM indicating the utility of 600 mg ceftaroline fosamil for S. aureus isolates with MIC ≤4 mg/L using q8h dosing.


  • Open Access

    Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam

    by Renu Singh, Aryun Kim, M. Angela Tanudra, Jennifer J. Harris, Robert E. McLaughlin, Sara Patey, John P. O'DOnnell, Patricia A. Bradford, Ann E. Eakin

    The combination of aztreonam/avibactam has promising activity against MDR Gram-negative pathogens producing metallo-β-lactamases (MBLs), such as New Delhi MBL-1. Pharmacokinetic (PK)/pharmacodynamic (PD) understanding of this combination is critical for optimal clinical dose selection. This study focuses on the determination of an integrated PK/PD approach for aztreonam/avibactam across multiple clinical Enterobacteriaceae strains. Six clinical Enterobacteriaceae isolates expressing MBLs and ESBLs were studied in an in vitro hollow-fibre infection model (HFIM) using various dosing regimens simulating human-like PK for aztreonam/avibactam. The neutropenic murine thigh infection model was used for in vivo validation against two bacterial strains. MIC values of aztreonam/avibactam for the isolates ranged from 0.125 to 8 mg/L. Using a constant infusion of avibactam at 4 mg/L, the aztreonam PK/PD index was observed as % fT>MIC. Studies performed in the presence of a fixed dose of aztreonam revealed that the efficacy of avibactam correlates best with percentage of time above a critical threshold concentration of 2–2.5 mg/L. These conclusions translated well to the efficacy observed in the murine thigh model, demonstrating in vivo validation of the in vitro PK/PD target. PK/PD evaluations for aztreonam/avibactam in HFIM yielded a single target across strains with a wide MIC range. This integrated approach could be easily applied for forecasting clinically efficacious doses for β-lactam/β-lactamase inhibitor combinations.